The TOP10 ranking of multinational pharmaceutical companies has once again become Johnson & Johnson's highest revenue, and Merck's most important research and development

As multinational pharmaceutical companies successively disclose their 2021 semi-annual reports, the ranking of multinational pharmaceutical companies has also changed accordingly

In terms of total revenue, the top 10 global pharmaceutical companies ranked in order are: Johnson & Johnson, Roche, Pfizer, AbbVie, Novartis, Bristol-Myers Squibb, Merck, GlaxoSmithKline, Sanofi, Takeda

According to the revenue statistics of the pharmaceutical business, the top 10 global pharmaceutical companies are ranked in order: Pfizer, AbbVie, Novartis, Johnson & Johnson, Roche, Bristol-Myers Squibb, Merck, Sanofi, Takeda, AstraZeneca

Total performance: Johnson & Johnson has the highest revenue, Merck & Co.

According to the ranking of total operating income, Johnson & Johnson ranked first with total revenue of US$45.

2021H1 performance TOP10 of multinational pharmaceutical companies (US$100 million)

After the acquisition of Allergan, AbbVie's business has become more diversified.

Pharmaceutical business: Pfizer returns to the championship, GSK falls out of the top ten

If ranked according to the revenue of the pharmaceutical business, Pfizer turned around with the new crown pneumonia vaccine and regained the championship after spinning off the mature pharmaceutical business of Pultron

GlaxoSmithKline (GSK)’s revenue comes from the three major components of pharmaceuticals, vaccines, and consumer health care.

Pfizer Pfizer

Total revenue in the first half of the year was US$33.

Mature innovative drug products such as Eliquis (Apixaban), Ibrance (Pipexilide) and Xtandi (Enzalutamide) are still the main factors driving Pfizer's performance growth

Pfizer's biosimilars have grown significantly, achieving revenue of US$560 million in the first half of the year, and reaching a lawsuit settlement with Johnson & Johnson for a biosimilar of infliximab, which may help Inflectra/Remsima to further increase its volume

Pfizer said that it will continue to promote the regulatory approval of the mRNA new crown vaccine

AbbVie

Total revenue in the first half of the year was US$26.

Humira's US market revenue increased by 7% year-on-year, and its international market revenue fell by 12.

Novartis

Novartis's revenue in the first half of the year was US$25.

Thanks to the expanding demand of various mainstream markets, the growth rate of Cosentyx is still strong.

According to Novartis’s forecast, 15 countries/regions will include Zolgensma in the reimbursement category in 2022, and it is expected to break into the $1 billion club this year and become a blockbuster drug
.

Johnson

Johnson & Johnson's total revenue in the first half of the year was US$45.
633 billion, a year-on-year increase of 16.
9%
.
Johnson & Johnson’s business income mainly includes pharmaceuticals, medical devices and consumer health care.
The pharmaceutical business’s revenue in the first half of the year was 24.
798 billion US dollars, an increase of 13.
3%
.
The overall growth trend of products in the pharmaceutical sector is similar to that of 2020.
The main products are still Stelara (usnumab), Darzalex (daratumumab), Imbruvica (ibrutinib), Tremfya (guselkumab), Erleada (Patamide) and several other products
.
Usnumab is the highest-selling product of all Johnson & Johnson products, and it is expected to continue to grow in the short term, but it may face the impact of biological drugs in the next three years
.

The growth rate of daratumomab exceeds 50%, which also allows Johnson & Johnson to maintain its leading position in the multiple myeloma (MM) market
.
Due to the impact of biosimilar drugs, Infliximab shrank to US$1.
665 billion in the first half of this year, a year-on-year decrease of 13.
5%
.
Therefore, Johnson & Johnson will also face some challenges
.

Roche

Roche's total revenue in the first half of the year was 30.
7 billion Swiss francs, an increase of 8% over the previous year
.
Among them, the pharmaceutical business revenue was 21.
6 billion Swiss francs (235.
63 US dollars), down 3%
.
The decline in the pharmaceutical business was mainly affected by biosimilar drugs and the new crown epidemic
.
Affected by biosimilar drugs, the sales of Roche's old "troika" further fell sharply
.
Multiple sclerosis drug Ocrevus took the lead, with sales reaching 2.
438 billion Swiss francs (2.
693 billion US dollars), an increase of 23%, and it was Roche's highest-selling product in the first half of the year
.
The hemophilia drug imicelizumab grew strongly, with sales in the first half of the year increasing by 45% year-on-year to 1.
393 billion Swiss francs ($1.
521 billion), becoming Roche's fastest-growing product
.
PD-L1 monoclonal antibody atelizumab was approved for the three major indications of small cell lung cancer, triple negative breast cancer, and hepatocellular carcinoma.
In the first half of the year, sales increased by 29%, and it has become Roche's TOP5 product
.

Specifically in the Chinese market, thanks to the strong sales of Pertuzumab, Alectinib, Atelizumab and Trastuzumab, Roche's pharmaceutical business in China grew by 3% in the first half of the year, with revenue reaching 1.
7 billion.
Swiss francs
.
The total revenue of Bristol-Myers Squibb BMS in the first half of the year was US$22.
776 billion, a year-on-year increase of 9%
.
The growth of BMS performance is mainly driven by the seven major products of lenalidomide, apixaban, nivolumab, abatacept, pomalidomide, dasatinib and ipilimumab.
In total Sales exceeded 20 billion U.
S.
dollars
.
Lenalidomide is currently the product with the highest sales of BMS.
The sales revenue in the first half of the year was US$6.
146 billion, a year-on-year increase of 6%, and it will hit a new high in 2021
.
The anticoagulant drug Apixaban achieved a revenue of US$5.
678 billion in the first half of the year, a year-on-year increase of 18%.
It is the fastest-growing product in the BMS "blockbuster"
.
In 2020, the global sales of this product will reach 9.
1 billion U.
S.
dollars, and it is expected to be among the tens of billions of drugs in 2021
.

Merck

Merck’s total revenue in the first half of the year was US$22.
029 billion, a year-on-year increase of 12%
.
The pharmaceutical business contributed USD 19.
218 billion in the first half of the year, a year-on-year increase of 12%
.
Merck’s performance was mainly driven by sales of pembrolizumab and HPV vaccines
.

In 2020, the global sales of Pembrolizumab (K drug) will reach US$14.
380 billion
.
In the first half of this year, K drug sales revenue was US$8.
078 billion, a year-on-year increase of 21%
.
Gardasil 9/Gardasil’s cumulative revenue for the first half of the year was US$2.
151 billion, a year-on-year increase of 23%
.
Merck’s current revenue mainly relies on anti-tumor products and vaccines.
The core products are Keytruda, olaparib and lenvatinib mesylate are drugs jointly promoted with other companies
.
In terms of product development, Merck said that it will continue to advance the development plan of its oncology product portfolio, and it is expected that more than 90 potential new indications will be approved by 2028
.

Sanofi

Sanofi's revenue in the first half of 2021 totaled 17.
3 billion euros
.
Among them, pharmaceutical revenue was 13.
2 billion euros (+1.
4%), and vaccine business revenue was 1.
94 billion euros (+5.
5%), for a total of 151.
4 euros (17.
98 billion US dollars)
.
In the first half of the year, the sales revenue of the blockbuster drug for atopic dermatitis and asthma, Duplizumab, reached 2.
29 billion euros, becoming Sanofi's product with the highest sales and the fastest growth rate
.

Sanofi plans to submit an application document for supplementary indications for the treatment of chronic spontaneous urticaria with Duplizumab in 2022
.
In February of this year, Sanofi set an annual sales target of 10 billion euros for Duplizumab
.
As the world’s only pharmaceutical company originating in Asia, Takeda’s total revenue in the first half of 2021 ranked 11th (approximately US$15.
925 billion) for global pharmaceutical companies, and its pharmaceutical business revenue ranked 10th in the world
.
Takeda is mainly engaged in the fields of gastrointestinal, rare diseases, tumors, nerves and other diseases
.
Ulcerative colitis and Crohn's disease treatment drug Entyvio (Velizumab) is Takeda's highest-income product, with sales of US$2.
18 billion in the first half of 2021
.
Attention deficit hyperactivity disorder product Vyvanse/Elvanse (Lydexamphetamine), reached 1.
373 billion US dollars
.
Shan Guohong, President of Takeda China, said in an interview with Medical Rubik's Cube on BioChina that from 2020, Takeda has launched a five-year development plan for "Wuju Future" and plans to launch more than 15 innovative products in China within five years.
Not only drugs for rare diseases, but also innovative treatments for tumors and digestive diseases
.

Slicon

AstraZeneca’s total revenue in the first half of the year was US$15.
54 billion, a year-on-year increase of 23%
.
Revenue in China was US$3.
209 billion (+21%), accounting for 21% of AstraZeneca’s total revenue
.
AstraZeneca's three major products, Teresa, Duvalizumab and Olapali, all maintained double-digit rapid growth
.

Ochinib's revenue in the first half of the year was US$2.
454 billion, a year-on-year increase of 22%, and it was AZ's highest-selling product
.
The PD-L1 monoclonal antibody, Vallizumab, had revenue of US$1.
16 billion in the first half of the year, a year-on-year increase of 22%
.
The revenue of PARP inhibitor olaparib was US$1.
13 billion, a year-on-year increase of 39%
.
In addition, the new anti-diabetic drug Da Gelie has an eye-catching net growth rate, with revenue of US$1.
359 billion, a year-on-year increase of 60%
.

Respiratory system drug budesonide formoterol inhalation revenue was 1.
371 billion US dollars, a year-on-year decrease of 5%
.
Ticagrelor fell by 11%, mainly due to the impact of domestic centralized sourcing.
Sales in emerging markets dropped by 38%
.